“BORDEAUX NEOBLADDER”: FIRST EVALUATION OF THE URODYNAMIC OUTCOMES

==inizio objective==

The intracorporeal orthotopic Y-modified “Bordeaux” neobladder (iYNB) was first described in 2016. No urodynamic evaluation of this neobladder has been performed yet.
Objective
To present the urodynamic features of the iYNB and incontinence specific health-related quality-of-life (HRQoL) outcomes.

==fine objective==

==inizio methodsresults==

We prospectively assessed 26 patients operated between September 2018-November 2020.
Robotic radical cystectomy (RARC) for malignant disease of the bladder and iYNB by a single surgeon.

==fine methodsresults==

==inizio results==

Mean age at surgery was 65.4 years. Mean follow-up was 27 months (12-38). Mean time for the neobladder reconstruction was 192 minutes (110-340). Mean maximum capacity was 431cm3 (range 200-553). The mean post-void residual was 101.6 ml (0-310) and the rate of clean intermittent catheterization was 17.6%. With the exception of a significant reduction in the volume of the first sensation of bladder fullness, no other statistically significant changes in the UDS parameters of both the storage and voiding phase were observed over time. Daytime and nighttime continence rate was 58.8% and 23.5%. Mean postoperative I-QoL score was 103.3 (89-110). Limitations include the small number of patients and short follow-up.

==fine results==

==inizio discussions==

Three months after surgery and in November 2021, consenting patients underwent clinical evaluation and multichannel urodynamics (UDS). The incontinence quality of life (I-QoL) questionnaire was used to evaluate HRQoL. Continence was classified into daytime and nighttime and clinically defined as the use of zero pads. A descriptive statistical analysis was performed.

==fine discussions==

==inizio conclusion==

The UDS evaluation of iYNB demonstrates that both the volumetric and pressure characteristics are acceptable and may enhance QoL. Prospective studies with larger numbers of patients and longer follow-up are needed to further evaluate the iYNB.
Patient Summary
The “Bordeaux” neobladder provides acceptable urodynamic outcomes. It is associated to high levels of health-related QoL and good rates of continent patients

==fine conclusion==

==inizio reference==

==fine reference==

STANDARD INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG) PROTOCOL VERSUS SEQUENTIAL INTRAVESICAL BCG AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS

==inizio objective==

Until January 2021, in response to the Bacillus Calmette-Guerin (BCG) shortage, we modified our adjuvant intravesical regimen for high grade (HG) non-muscle invasive bladder cancer (NMIBC) patients who experienced low grade adverse events (like shiver and facial swelling) during the first two doses of BCG (1). The aim of this study was to analyze the oncological outcomes and complications of six BCG instillations versus a protocol of sequential intravesical BCG and device-assisted chemo-hyperthermia (C-HT) treatment (2). Mitomycin C was delivered by the COMBAT BRS system.

==fine objective==

==inizio methodsresults==

We compared 36 patients (Group A) whose underwent six BCG instillations and 24 patients (Group B) whose underwent the sequential therapy (BCG, BCG, C-HT, C-HT, C-HT, BCG) from January 2021 to June 2022. Six weeks later, a control cystoscopy was performed. All patients with no evidence of disease at the follow up cystoscopy received a maintenance treatment with C-HT for three months and a subsequent cystoscopy after six weeks. All data were recorded in a prospectively maintained database and retrospectively examined. Yates’s chisquared (χ2) and Student’s t-tests were used to compare the statistical significance of differences in proportions and means, respectively. Statistical analyses were performed using SPSS V23.0 (Armonk, NY: IBM Corp.), defining statistical significance at p <0.05. ==fine methodsresults== ==inizio results== There were no significant differences in the demographics and baseline characteristics among the groups (age, BMI, ECOG performance status, gender, smoking status, diabetes, number of tumors, tumor size, recurrence rate, pathologic state, concomitant CIS, tumor on second TURB, prior history of UTUC, previously treated with MMC, BCG failure group; p>0.05). No significant differences were found in recurrence (9/36 group A vs 4/24 group B; p=0.6543) and progression (2/36 group A vs 1/24 group B; p=0.7168) rates after induction course between Group A and B (Table 2). No significant differences were found in recurrence (2/27 group A vs 1/20 group B; p=0.7875) and progression (1/27 group A vs 1/20 group B; p=0.6079) rates after first maintenance course with C-HT. Low-grade adverse events (grade I-II bladder spams and frequency/urgency) occurred in 3 out 36 patients in group A and in 2 out 24 in group B (p=0.6336).

==fine results==

==inizio discussions==

As a result of internalization and presentation of BCG, secretion of cytokines and chemokines, adverse effects may occur (3). Local and systemic complications include fever, malaise, bladder irritation (urination frequency, dysuria, or mild hematuria), granulomatous prostatitis, testicular abscess, pyelonephritis, spondylodiscitis, pneumonitis etc. (1). Fever is suggestive of immune system activation and is associated with a more favorable antitumor response. C-HT can be considered a viable alternative for treatment in BCG failure or intolerant HG-NMIBC patients, avoiding or postponing radical cystectomy in some particular subclasses of patients (4), showing a low number of adverse events (5). C-HT induce immunogenic cell death (ICD), resulting in increased immunity. It is possible that CHT induces ICD or activates the immune system through heat shock proteins or other factors. Hyperthermia has an important impact on the immune system resulting in augmented activation of NK cells that destroy heat-stressed cancer cells. Moreover, thermotherapy induces heat shock proteins expression on the cancer cell surface. In fact, post-treatment NLR (neutrophil-to-lymphocyte ratio) can be considered a biomarker for response to the induction course of CHT (6). Sequence treatment could, therefore, benefit from immune system activation by a dual mechanism. The sequential treatment (BCG+C-HT) showed similar recurrence and progression outcomes compared to BCG conventional course.

==fine discussions==

==inizio conclusion==

Our preliminary data in the BCG+ C-HT sequence group show promising results in terms of efficacy and safety potentially representing a viable alternative HG-NMIBC treatment.

==fine conclusion==

==inizio reference==

1-Guallar-Garrido S., Julián E. Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update. Immunotargets Ther. 2020 Feb 13;9:1-11.

2-Griffiths T.R.L., Grice P.T., Green W.J.F., Goddard J.C., Kockelbergh R.C. One-year follow-up results after sequential intravesical bacillus Calmette-Guérin and device-assisted chemo-hyperthermia (Mitomycin C delivered by the Combat BRS system) for high risk non-muscle invasive bladder cancer patients…a bacillus Calmette-Guérin-sparing strategy-The Journal of urology, Vol.197, Issue 4, e367, April 2017, AUA, Boston

3- Gil Redelman-Sidi, Michael S. Glickman and Bernard H. Bochner The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat. Rev. Urol. 11, 153–162 (2014);

4-Chiancone F., Fabiano M., Fedelini M., Meccariello C., Carrino M., Fedelini P. Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. Cent European J Urol. 2020;73(3):287-294.

5-Chiancone, F.; Carrino, M.; Fedelini, M.; Fabiano, M.; Persico, F.; Meccariello, C.; Fedelini, P. The Role of Protopine Associated With Nuciferine in Controlling Adverse Events During Hyperthermic Intravesical Chemotherapy Instillations. A Nutraceutical Approach to Control Adverse Event During Intravesical Instillations. Arch Ital Urol Androl 2020, 92.

6-Chiancone F., Fabiano M., Carrino M., Fedelini M., Meccariello C., Fedelini P. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscleinvasive bladder cancer after bacillus Calmette–Guérin failure, Arab Journal of Urology. 2021, 19:1, 86-91.

==fine reference==

Evaluation of perioperative outcomes and complications of patients undergoing radical cystectomy with intracorporeal reconstruction for bladder cancer following a new Enhanced Recovery after Surgery (ERAS) protocol

==inizio objective==

Enhanced recovery after surgery (ERAS) concepts are implemented in various surgical disciplines to improve morbidity, enhance recovery, and reduce hospital stays. To describe our new ERAS protocol used in patients (pts) who underwent robotic radical cystectomy (RARC) with intracorporeal ileal conduit (IIC) or ileal intracorporeal neobladder (NB) reconstructions for bladder cancer. First evaluation after 5 years of RARC in a high volume referred center.

==fine objective==

==inizio methodsresults==

86 RARC with intracorporeal reconstruction were performed in our centre from 2016 to July 2022, of these 52 pts were IIC and 34 were ileal NB reconstruction. All the procedures were performed by the same surgeon. All the pts were selected for our new ERAS protocol. The protocol consists of a preoperative counseling and education of patients and caregivers with optimization of medical and nutrition conditions with use of immunostimulant. The day before surgery the pt starts antithrombic prophylaxis with enoxaparine 4000 UI 1 fl administered postoperatively following EAU guidelines. Antibiotics prophylaxis with piperacillin plus tazobactam starts the day before surgery and then for 48h. To create loading carbohydrate the pt takes 800 ml of maltodextrin the evening before and 200 ml the morning of surgery. After the procedure the nasogastric tube (NGT) is removed and support therapy consists in metoclopramide 3 times day for three days, paracetamol 1 gr 3 times days for 48 hours and 2000 ml of normal saline for 1 day. We normally encourage mobilization the first postoperative day and then progressively day by day, we suggest use of chewing gum during the day. Oral nutrition can start with soft food the 2nd day after surgery, increasing progressively. We analyzed perioperative surgical, functional outcomes and complications.

==fine methodsresults==

==inizio results==

Median age was 70,3 yrs (range 49-87). Mean BMI was 27 (range 19-40). Mean follow-up was 6 months. The median operative time was 332 (range 185-546 min). The median length of hospital stay was 10,6 (range 5-27). In 8 (6,9%) pts NGT was repositioned after 48 hours from surgery because of nausea and vomit and in 9 pts (7,7%) was removed some days after surgery. Mean bowel canalization was 2 days, mean stool canalization was 5 days later. 22 pts (18,9%) developed complications clavien dindo (CD) <2 (10 anemizations, 10 urinary infection or sepsis, 2 TEP, 1 lymphocele, 1 urinoma) and in 2 cases (1,7%) CD>3b, one reintervention for abdominal occlusion and one for laparocele.

==fine results==

==inizio discussions==

==fine discussions==

==inizio conclusion==

These initial results show that a careful nutritional evaluation and a progressive rehabilitation are fundamental for the rapid recovery of bowel canalization in case of RARC with intracorporeal ileal reconstructions. This first analysis of our new ERAS protocol shows promising results, a multidisciplinary approach with nutritionist and physiotherapist can improve the recovery of the canalization after surgery.

==fine conclusion==

==inizio reference==

==fine reference==

Single-session laparoscopic cystectomy and nephroureterectomy: is it real and useful choice of treatment or fiction?

==inizio objective==

Urothelial cancer is the fourth most common malignancy in developed countries, affecting more frequently the urinary bladder and in only 5–10% of cases the upper urinary tract [1]. Furthermore, an association between these two cancers was found in the 17% of cases [2]. Open radical cystectomy is still considered the gold standard treatment for muscle-invasive or high risk and recurrent non-muscle-invasive bladder tumors, Bacillus Calmette-Guerin (BCG) refractory, relapsing and unresponsive T1G3 tumors [3, 4]. Open radical nephroureterectomy with bladder cuff excision is the standard treatment for high risk upper urinary tract cancer [5]. Simultaneous nephroureterectomy and radical cystectomy can be performed in patients affected by recurrent high grade or muscle-invasive bladder cancer and concomitant upper urinary tract cancer or non-functional kidney [6]. Several studies have shown the advantages of laparoscopic approach (compared with open techniques), especially when performed by experienced surgeons. These advantages include: fewer intraoperative and postoperative complications, decreased intraoperative blood loss, less need of analgesics, shorter hospital stay and earlier recovery [7–9], having at the same time functional and oncological results similar to those of open surgery [10, 11]. We report our experience with simultaneous laparoscopic radical cystectomy and nephroureterectomy in three patients.

==fine objective==

==inizio methodsresults==

Three male patient (aged between 65 and 75 years) affected by recurrent polyfocal high grade or muscle-invasive bladder cancer and an associated renal pathology (in one case right renal pelvis carcinoma of 16 mm in diameter on CT scan while in other cases while in the other two cases neoplastic involvement of the left distal ureter extending up to the middle tract, with concomitant hydronephrosis) underwent simultaneous radical cystectomy and nephroureterectomy performed by laparoscopic approach. According to the pre-operative imaging study, the two tumors were organ-confined. The Clavien–Dindo classification was used to evaluate post-operative complications. We performed laparoscopic transperitoneal approach, using the trocars arrangement shown in the figure. After positioning a catheter into the bladder, the patient was first placed in lateral (right or left) decubitus for the nephroureterectomy. After inducing pneumoperitoneum using a Verres needle, a 12-mm trocar (used as the camera port and indicated in the figure as ‘X’) was placed 2 cm laterally to the right or the left of the umbilicus (based on the kidney to be removed). The other two 12-mm trocars were placed in line, in the right or left pararectal area. During this surgical procedure the renal artery and the renal vein were identified, clamped with Hem-o-lock clips and sectioned between. A perifascial dissection of the kidney was performed, preserving the adrenal gland. For the next step of the surgery, radical cystectomy and bilateral pelvic lymph node dissection, the patient was positioned in dorsal decubitus, in a Trendelenburg position. The camera trocar was the same as for the right or left nephroureterectomy. Three other trocars (two 5- mm and one 12-m trocars) were placed in addition. The 12-mm trocar was placed, inferior to the umbilicus, in the left pararectal area whereas the two 5-mm trocars were placed in the left and right lower quadrant, proximal to the anterior–superior iliac spine. For bladder dissection, its vascular peduncles were secured with mechanical stapler and divided. In this way, the lateral plane was dissected, bilaterally. Finally, the urethra was divided distal from the prostatic apex using cold scissors. The pelvic lymphadenectomy was performed around the iliac vessels and obturatory fossa bilaterally. Two tubular drains were used, one in the right or left renal lodge and the other in the pelvic cavity. Urinary diversion as a unilateral ureterocutaneostomy was constructed by pulling the left or the right ureter through the hand port incision (specifically using the 12-mm trocar on the left or right side). The ureter was catheterized with a mono J stent. All specimens were placed in an endobag, removed through a midline incision and sent to the pathological examination. The operative field was inspected for bleeding or injury.

==fine methodsresults==

==inizio results==

Regarding perioperative data, we used six trocars and, in all three patients, the mean operative time was almost 4 hours, with blood loss (mL) less than 1000 mL. Regarding intraoperative data, in one patient the hospital stay (days) was 13 days but in two other patients it was less than 10 days. The surgical margins were free of tumor and the follow-up period was 16 months. As regards the pathological stages, one patient was affected by T1G3 bladder cancer while in two other cases the bladder tumor was infiltrated in the muscle (T2G3). In all patients the tumor of the upper urinary tract (affecting the renal pelvis in one patient while the ureter in the remaining cases) presented this pathological stage: T1G3. In all cases the pathological examination did not reveal any pelvic lymph nodes affected by neoplasia. After discharge, the patients returned to their normal activities without limitations after 3 weeks. More than a year after surgery, the patients are still alive, showing no tumor relapse of at the established instrumental controls.

==fine results==

==inizio discussions==

We successfully performed laparoscopic radical nephroureterectomy and cystectomy with pelvic lymph node dissection in a single-session, without the need for conversion to open surgery. According to literature data, minimally invasive surgery can minimize the complications and improve the recovery [7–9]. Performing a similar surgery with a laparoscopic approach is very demanding. To have oncological safety, intraoperatively, particular attention must be paid to avoid tumor leakage. In addition, the sample must be extracted en bloc immediately into an endobag, with the bladder neck closed to avoid contact of the urine with the abdominal cavity. Another important oncological aspect is the extent of lymphadenectomy. According to literature data, extended lymph node dissection during radical cystectomy is possible even when a minimally invasive approach is chosen [12]. We removed more than 20 lymph nodes in all three cases. Several studies showed that the oncological safety of a laparoscopic approach is similar to that of open surgery [10, 11]. Although an open surgery including nephroureterectomy and radical cystectomy involve one large midline incision with greater morbidity and longer convalescence, the laparoscopic approach implicates very small trocar incisions and an incision of ∼4–5 cm to remove the specimen. In effect, the specimen can be removed through a small lower midline incision, Pfannenstiel incision or transvaginally in female patients. We preferred a small midline incision for the specimen removal due to the lower risk of evisceration. According to small series, performing in a single session laparoscopic nephroureterectomy and cystectomy is feasible, with good oncological results and early recovery [7–9, 10, 11]. A large-scale prospective study will be necessary to provide more information on this surgery in the future.

==fine discussions==

==inizio conclusion==

In conclusion, the laparoscopic approach is widely spreading in urology and, in some cases, it has become a standard of care. In selected cases, performing in a single-session laparoscopic radical cystectomy and nephroureterectomy is oncologically safe and technically reproducible, offering oncological and functional results similar to those of open surgery. In addition, choosing a minimally invasive approach, the cosmetic results are better, also with faster post-operative recovery and lower bleeding rates.

==fine conclusion==

==inizio reference==

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. 

2. Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013;31:141–5. 

3. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75. 

4. World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, et al. Urinary diversion. Urology 2007;69: 17–49.
5. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collabora- tion. Cancer 2009;115:1224–33.
6. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778–92.
7. Tang K, Li H, Xia D, Hu Z, Zhuang Q, Liu J, et al. Laparoscopic versus open radical cystectomy in bladder cancer: a system- atic review and meta-analysis of comparative studies. PLoS One 2014;9:e95667.
8. Khan MS, Challacombe B, Elhage O, Rimington P, Coker B, Murphy D, et al. A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy. Int J Clin Pract 2012;66:656–62.
9. Veccia A, Antonelli A, Francavilla S, Simeone C, Guruli G, Zargar H, et al. Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases. World J Urol 2020;38:845–52.
10. Rassweiler J, Godin K, Goezen AS, Kusche D, Chlosta P, Gaboardi F, et al. Radical cystectomy – pro laparoscopic. Urologe A 2012;51:671–8.
11. Liu F, Guo W, Zhou X, Ding Y, Ma Y, Hou Y, et al. Laparo- scopic versus open nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta- analysis. Medicine (Baltimore) 2018;97:e11954.
12. Desai MM, Berger AK, Brandina RR, Zehnder P, Simmons M, Aron M, et al. Robotic and laparoscopic high extended pelvic lymph node dissection during radical cystectomy: technique and outcomes. Eur Urol 2012;61:350–5.

==fine reference==

DIAGNOSTIC VALUE OF XPERT® BC DETECTION, BLADDER EPICHECK®, UROVYSION® FISH AND CYTOLOGY IN THE DETECTION OF UPPER URINARY TRACT UROTHELIAL CARCINOMA

==inizio objective==

Upper urinary urinary tract tumours (UTUC) account for 5-6% of all UC with an estimated incidence of 2 cases per 100.000 citizen per year (1).
Following the current European Association of Urology (EAU) guidelines, diagnosis and staging can be performed with Computed Tomography (CT), urography and flexible ureterorenoscopy (URS) (2).
At the moment, no marker is recommended by the EAU guidelines for diagnosis or follow up of UTUC, albeit it would be necessary to avoid a delayed diagnosis.
The aim of our study was to evaluate the performance and the clinical utility of the Xpert® bladder cancer (BC) Detection and the Bladder Epicheck® test in the detection of UTUC and compare it with cytology and the Urovysion® FISH test using URS and/or histology as gold standard.

==fine objective==

==inizio methodsresults==

After approval of the local institutional ethic committee, 121 analyses were performed in 79 patients (median age 71 years). A total of 97 analyses (80.2%) were evaluable for cytology and all 3 markers and included in the study.
Samples were analyzed with UT urinary cytology, Xpert® BC Detection, Bladder Epicheck® and Urovysion® FISH.
Patients underwent URS under general anesthesia and, if positive, a UT biopsy.

==fine methodsresults==

==inizio results==

31 URS resulted positive, with 26 low grade (83.9%) and 5 high grade (16.1%) tumours.
Overall sensitivity was 100% for Xpert® BC Detection, 41.9% for cytology, 64.5% for the Bladder Epicheck® test and 87.1% for Urovysion® FISH test.
The sensitivity of Xpert® BC Detection was 100% in both, LG and HG tumours, sensitivity of cytology increased from 30.8% in LG to 100% in HG tumours, for Bladder Epicheck® from 57.7% in LG to 100% in HG and of Urovysion® FISH from 84.6% in LG to 100% in HG tumours.
Specificity was 4.5% for Xpert® BC Detection, 93.9% for cytology, 78.8% for Bladder Epicheck® and 81.8% for Urovysion® FISH. PPV was 33% for Xpert® BC Detection, 76.5% for cytology, 58.8% for Bladder Epicheck® and 69.2% for Urovysion®. NPV was 100% for Xpert® BC Detection, 77.5% for cytology, 82.5% for Bladder Epicheck® and 93.1% for Urovysion®.

==fine results==

==inizio discussions==

The limitation of this study is the low number of patients who had all 4 tests performed at the same time and the monocentric study design. Further multicentric studies with standardized sampling techniques and standardized FISH evaluation would be necessary.

==fine discussions==

==inizio conclusion==

Sensitivity of cytology is low in LG tumours thus having a high specificity. Manipulation during URS seems to decrease the specificity of the Xpert® BC Detection, limiting the usefulness in the diagnosis of UTUC. Bladder Epicheck® shows an acceptable sensitivity and specificity and along with cytology it could be a helpful ancillary method for the detection of UTUC and useful in the follow up of patients after UTUC. However, Urovysion® seems to remain a good choice of a marker for the detection of UTUC and in the follow up of these patients

==fine conclusion==

==inizio reference==

1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. CA Cancer J Clin 2019; 69 (1): 7-34.
2. Rouprêt M, Babjuk M, Burger M, et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma. European Association of Urology. Update March 2020. http://uroweb.org/guidelines/compilations-of-all-guidelines/

==fine reference==

Bordeaux technique for intracorporeal Orthotopic ileal neobladder.:illustration of surgical tricks and evaluation of perioperative outcomes in a referred center

==inizio abstract==

Orthotopic neobladder (ONB) reconstruction is a continent urinary diversion procedure increasingly used in selected patients with muscle-invasive bladder cancer following radical cystectomy (RC). Various techniques are currently used and have shown satisfactory outcomes. The present video is intended to illustrate key surgical steps, tricks and preoperative outcomes of our standardized technique of ONB.

In our center 97 RARC were from 2016 to 2021. Of these, 33 pts who selected for NB reconstruction. All the procedures were performed by the same surgeon. All the pts were subjected for an enhanced recovery after surgery (ERAS) protocol.
The tecquinique used was intracorporeal Y-modified neobladder (“Bordeaux Neobladder”).
It consists in a reconstruction with an ideal segment of 40 centimeters, isolated approximately 25 centimeters from the ileocecal valve. At medium this segment is open and a double semicircular uretral-ileal anastomosis is obtained. Both ends of the selected ileal segment are then divided with the aid of a laparoscopic 60 millimeters intestinal stapler.
Ileal continuity is restablished through an aniso-peristaltic anastomosis.
The middle anti mesenteric part of the selected ileal segment is opened with scissors in order to obtain its detubularization. The medial margins are sutured and the posterior plate is created. The anterior bladder neck is then remodelled and the wire used for the posterior reconstruction is used to connect the end of the posterior reconstruction to the anterior bladder neck. Two lateral sutures are performed to close the neobladder until almost 5 centimeters before to complete the closure of the lateral wall. The ureters are spatulated and then reimplanted following a Wallace technique at the open ends of neobladder limbs. Once the posterior reconstruction of the anastomosis is completed, a single j stent is percutaneously inserted on a guidewire and then the anastomosis is completed.

==fine abstract==